^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH wild-type

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    Entrez ID:
    3417; 3418
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=94, Recruiting, Mayo Clinic | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    WSD0628
    7d
    Isocitrate Dehydrogenases Idh1 and Idh2 Regulate Pronephric Morphogenesis in Xenopus laevis. (PubMed, Dev Reprod)
    Notably, the oncogenic idh1*R132H variant also rescued the pronephric defects induced by idh1 knockdown, indicating that its neomorphic activity is absent under embryonic metabolic conditions. These findings identify Idh1 and Idh2 as key regulators of pronephric morphogenesis and reveal a developmental function of Idh1 that is distinct from its canonical catalytic role.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type • IDH1 R132
    7d
    Anti-GD2 ADC M3554 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Oct 2026 --> Apr 2027
    Trial primary completion date • First-in-human
    |
    IDH wild-type
    8d
    PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)
    P1, N=51, Recruiting, Duke University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    MVR-C5252
    8d
    STAR-GBM: A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Myosin Therapeutics Inc. | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jun 2027 --> Feb 2032 | Initiation date: Nov 2025 --> Apr 2026
    Enrollment open • Phase classification • Trial completion date • Trial initiation date • First-in-human
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    9d
    Extracranial Metastases in Glioblastoma, IDH-Wildtype: A Case Series. (PubMed, Diagnostics (Basel))
    All patients underwent surgical resection followed by temozolomide-based chemoradiation; two received fotemustine and bevacizumab, and one underwent re-irradiation. EM can arise despite MGMT-promoter methylation in IDH-wildtype GBM. Imaging red flags (high perfusion, surface contact, necrotic/FDG-avid cervical nodes) and clinical cues (axial pain, cytopenias, neck masses) should prompt early systemic staging (CT/PET-CT) and targeted tissue confirmation to advance management.
    Journal
    |
    TP53 (Tumor protein P53) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    TP53 mutation • TP53 wild-type • MGMT promoter methylation • IDH wild-type
    |
    Avastin (bevacizumab) • temozolomide • Muphoran (fotemustine)
    9d
    SC9/ABX: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Northwestern University | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH wild-type • IDH1 R132
    |
    carboplatin • albumin-bound paclitaxel
    10d
    Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma (clinicaltrials.gov)
    P3, N=200, Recruiting, Vastra Gotaland Region | Not yet recruiting --> Recruiting | Trial completion date: Dec 2031 --> Dec 2033 | Trial primary completion date: Dec 2028 --> Dec 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    temozolomide • lomustine
    10d
    NF118: Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma (clinicaltrials.gov)
    P2, N=55, Not yet recruiting, University of Alabama at Birmingham
    New P2 trial
    |
    TP53 (Tumor protein P53) • NF1 (Neurofibromin 1)
    |
    TP53 mutation • IDH wild-type
    |
    Gomekli (mirdametinib)
    12d
    Seizure-presenting IDH-wildtype glioblastoma and the upregulation of a synaptic signature. (PubMed, J Neurosurg)
    In IDH-wildtype GBM, tumors presenting with seizures had smaller volumes than those presenting with other signs. Transcriptionally, seizure presentation in IDH-wildtype GBM correlated with the upregulation of synaptic and ionic pathways, with SLC17A8 holding independent predictive value for seizure presentation.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • IGF1 (Insulin-like growth factor 1) • ADAMTS2 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 2)
    |
    IDH wild-type